Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

Published:

20240601 -

The International Journal of Tuberculosis and Lung Disease

Author(s):

D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja

Tags:

Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, Regimen Change, TB Drug Market